R. Young

nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial

P. Beale, P. Mainwaring, M. Botteman, 2018, Asia-Pacific journal of clinical oncology.

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

V. Gebski, N. Pavlakis, V. Ganju, 2016, British Journal of Cancer.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

J. Herndon, J. Crawford, S. Mehdi, 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

W. Scheithauer, J. Tabernero, V. Heinemann, 2014 .

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.